1I4 Stock Chart & Stats
€0.02
<€0.01(10.00%)
At close: 4:00 PM EST
€0.02
<€0.01(10.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00K
Market Cap
€23.61M
Enterprise Value€39.94
Total Cash (Recent Filing)€2.03M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume0
30 Day Avg. Volume4,000
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraged Balance SheetThe move to zero debt and positive equity materially reduces leverage compared with 2021, when debt was elevated and equity was negative. This improves financial flexibility and lowers balance-sheet pressure, although the smaller equity base still limits the cushion available to absorb continued losses.
Improved Gross MarginThe sharp improvement in gross margin shows that the underlying offering can retain a meaningful portion of revenue after direct costs. If maintained, this provides a stronger base for operating leverage and future profitability, even though current overhead and operating losses remain substantial.
Focused Digital Health ModelA focused digital health model centered on maternity and female health gives HeraMED a defined product and clinical-use domain rather than a broad, undifferentiated offering. That specialization can support clearer product development and customer targeting over the medium term.
Bears Say
Persistent UnprofitabilityOngoing operating and net losses indicate that the current revenue base is not covering the company’s operating cost structure. Without a sustained improvement in operating leverage, continued losses can erode equity and restrict the ability to fund product development or expansion internally.
Recurring Cash BurnPersistent negative operating and free cash flow means the business consumes cash while it operates, rather than funding itself through internally generated resources. Even though 2025 cash burn improved versus 2024, the absence of sustained positive cash generation creates ongoing funding and liquidity pressure.
Revenue ContractionRecent revenue contraction weakens the scale needed to absorb fixed operating costs and delays the path to profitability. Combined with the company’s volatile revenue history, the decline suggests that demand expansion has not yet become consistent enough to support durable operating leverage.
HeraMED Ltd. News
1I4 FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest stock price was €0.01 and its highest was €0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is €23.61M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 168 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Aug 21, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,158,636,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in DE:1I4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
114.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HeraMED Ltd.
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―